Clinical Efficacy of Artemether-Lumefantrine in Congolese Children with Acute Uncomplicated Falciparum Malaria in Brazzaville

Table 2

Artemether-lumefantrine efficacy in children in Brazzaville.

	Number	Percentage	95% CI
No. of patients	77
Responses on day 14
Withdrawn or loss to follow up	4	5.2	1.4–12.8
Eligible	73	94.8	87.2–98.6
ETF	1	1.4	0–7.4
ACPR	72	98.6	92.6–100
Responses on day 28 (PCR uncorrected)
Withdrawn or loss to follow up	8	10.4	4.6–19.4
Eligible	69	89.6	80.6–95.4
Treatment failure	7	11.3	4.2–19.8
ETF	1	1.5	0.05–7.8
LCF	2	2.9	0.4–10.1
LPF	4	5.5	1.6–14.2
ACPR^†	62	89.9	80.2–95.8
Responses on day 28 (PCR corrected)
Withdrawn or loss to follow up	8	16.9	9.3–27.1
Eligible	69	86.6	80.6–5.4
Treatment failure	2	2.9	0.4–10.0
ETF	1	1.4	0.04–7.8
Recrudescence	1	1.4	0.04–7.8
ACPR^‡	67	97.1	89.9–99.6
PCR analysed isolates
Recrudescence	1	16.7	0.4–64.1
Reinfection	5	83.3	35.9–99.6

95% CI: 95% confidence intervals; ETF: early treatment failure; LCF: late clinical failure; LPF: late parasitological failure; ACPR: adequate clinical and parasitological response.
^†Of these patients, 86.5% (95% CI, 71.2–95.5%) under 5 years old had ACPR response, while 93.8% (95% CI, 79.2–99.2%) of the patients aged between 5 and 10 years old responded with ACPR. The difference in ACPR proportions between these two subpopulations of patients was not significant (𝑃=0.6, chi-square test).
^‡Of the patients responding with ACPR, 94.1% (95% CI, 80.3–99.3%) were aged <5 years old and 100% (95% CI, 88.4–100%) were aged between 5 and 10 years old. The difference in ACPR proportions between the two subpopulations of patients was not significant (𝑃=0.5, chi-square test).